Cited by 98Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychotherapy Techniques and Applications

Cognitive-Behavioral Therapy to Prevent Relapse in Pediatric Responders to Pharmacotherapy for Major Depressive Disorder

Open access
Kennard, Betsy D., Emslie, Graham J., Mayes, Taryn L., Nightingale-Teresi, Jeanne, Nakonezny, Paul A., Hughes, Jennifer L., Jones, Jessica M., Tao, Rongrong +2 more·2008·Journal of the American Academy of Child & Adolescent Psychiatry

Abstract

Objective We present results of a feasibility test of a sequential treatment strategy using continuation phase cognitive-behavioral therapy (CBT) to prevent relapse in youths with major depressive disorder (MDD) who have responded to acute phase pharmacotherapy. Method Forty-six youths (ages 11-18 years) who had responded to 12 weeks of treatment with fluoxetine were randomized to receive either 6 months of continued antidepressant medication management (MM) or antidepressant MM plus relapse prevention CBT (MM+CBT). Primary outcome was time to relapse, defined as a Childhood Depression Rating Scale-Revised score of 40 or higher and 2 weeks of symptom worsening or clinical deterioration warranting alteration of treatment to prevent full relapse. Results Cox proportional hazards regression, adjusting for depression severity at randomization and for the hazard of relapsing by age across the trial, revealed that participants in the MM treatment group had a significantly greater risk for relapse than those in the MM+CBT treatment group (hazard ratio = 8.80; 95% confidence interval 1.01-76.89; chi = 3.86, p =.049) during 6 months of continuation treatment. In addition, patient satisfaction was significantly higher in the MM+CBT group. No differences were found between the two treatment groups on attrition rate, serious adverse events, and overall global functioning. Conclusions These preliminary results suggest that continuation phase CBT reduces the risk for relapse by eightfold compared with pharmacotherapy responders who received antidepressant medication alone during the 6-month continuation phase.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/chi.0b013e31818914a1

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In two trials, acute phase treatment lasted 12 weeks before maintenance and re-randomisation.

    “In two trials, acute phase treatment lasted 12 weeks (Emslie 2008; Kennard 2008), at which point participants entered a maintenance phase and were re-randomised, potentially to a new treatment arm.”

    From Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents (2012) · cites this paper as Kennard 2008

    The Methods (Procedures; page not provided) describe 12 weeks of acute fluoxetine treatment, followed by randomization of responders into continuation-phase treatment. The paper describes this as their first randomization, not re-randomization; participants had received open treatment during the acute phase. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Three trials contained children and adolescents aged 7-18; one contained adolescents aged 13-19.

    “Three trials contained both children and adolescents between the ages of 7 and 18 years (Emslie 2004; Emslie 2008; Kennard 2008) and one contained adolescents between 13 and 19 years (Cheung 2008).”

    From Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents (2012) · cites this paper as Kennard 2008

    The Methods (Procedures) specify participants aged 11–18, and the Results (Participant Characteristics) report that randomized participants ranged from 11 to 18. Kennard 2008 therefore supports the upper age limit of 18, but not the lower limit of 7 attributed to it. The separately cited Cheung trial is not assessed here. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Medication trials all involved SSRIs; three administered fluoxetine and one sertraline.

    “Medication trials all involved SSRIs; three trials administered fluoxetine (Emslie 2004; Emslie 2008; Kennard 2008) and one involved sertraline (Cheung 2008).”
  • Sample sizes in acute phase ranged 66-219; in relapse-prevention phase ranged 22-102.

    “Sample sizes in the acute phase of treatment ranged from 66 (Kennard 2008) to 219 participants (Emslie 2004), and in the relapse-prevention phase ranged from 22 (Cheung 2008) to 102 participants (Emslie 2008).”
  • During acute treatment, one trial openly treated all participants with sertraline and two others with fluoxetine.

    “During the acute phase of treatment, one trial openly treated all participants with sertraline (Cheung 2008) and two others treated participants with fluoxetine (Emslie 2008; Kennard 2008).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kennard, B. D., Emslie, G. J., Mayes, T. L., Nightingale-Teresi, J., Nakonezny, P. A., Hughes, J. L., Jones, J. M., Tao, R., Stewart, S. M., & Jarrett, R. B.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
Kennard, Betsy D.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2008-12
Volume
47
Issue
12
Pages
1395-1404
ISSN
0890-8567 (ISSN-L)
OpenAlex
W2048973211
Cited by
98
References
39
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 6 · 2015: 8 · 2014: 17 · 2013: 9 · 2012: 11
FWCI
5.86
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (R34MH072737, R01-MH39188, K24MH001571, MH K24 01571, R01MH039188)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
major depressive disorder, childhood depression, relapse prevention, cognitive behavioral therapy, antidepressant maintenance, fluoxetine, sequential treatment strategy, treatment-resistant depression, patient satisfaction, attrition
MeSH terms
Adolescent, Child, Combined Modality Therapy, Depressive Disorder, Major, Major Depressive Disorder, Family Therapy, Feasibility Studies, Female, Fluoxetine, Humans, Male, Personality Inventory, Psychometrics, Cognitive Behavioral Therapy, Proportional Hazards Models, Antidepressive Agents, Second-Generation, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review